Our Science
Evidence for drug resistance due to Efflux Pump (EP) overexpression has been shown in nearly all solid tumors as well as in hematologic malignancies. An estimated 25% of all patients with cancer will receive chemotherapy as part of their treatment and as many as 80% will develop drug resistance. In addition to chemotherapy, other small molecules such as tyrosine kinase inhibitors are known substrates for Efflux Pumps, which can lead to drug resistance.
Efflux Pumps Contribute to Drug Resistance
Drug Sensitive Tumor Cell
Normal expression of EPs allows cytotoxic drugs to remain in the tumor, increasing cell death
Drug Resistant Tumor Cell
Overexpressed EPs expel cytotoxic drugs and promote tumor cell survival
Cytotoxin
Efflux Pump
